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18F-FDG : 18F-Fluorodeoxiglucose 
CRP : C-reactive protein 
CT : computed tomography 
ESR : erythrocyte sedimentation rate 
GCA : giant cell arteritis 
IQR : interquartile range 
LVV : large-vessel vasculitis 
PMR : polymyalgia rheumatica 
PET/CT : positron emission tomography/computed tomography 
TBR : target-to-background ratio 
SD : standard deviation 





Objective. 18F-FDG PET/CT has proved to be of potential value for early diagnosis of 
large-vessel vasculitis (LVV), which frequently involves the aorta. However, its role in the 
follow-up of these patients has not been well established. Our aim was to evaluate the 
contribution of 18F-FDG PET/CT in this clinical situation.  
Methods. This study included 37consecutive patients (28 women, 66.5±9.9 y.) with an 
initial 18F-FDG PET/CT positive for LVV and a mean±standard deviation follow-up PET/CT 
of 7.5±2.9 months after the initial scan. A semiquantitative analysis of aortic wall uptake 
was performed calculating the target-to-background ratio (TBR: aortic wall uptake divided 
by blood pool uptake). The initial and follow-up TBR as well as the clinical and laboratory 
outcome were compared.  
Results. Overall, the mean TBR decreased from 1.7±0.5 at the initial scan to 1.5±0.3 at 
the time of follow-up (p=0.0001). In the 21 patients who experienced clinical improvement 
following therapy the TBR also decreased from 1.8±0.6 to 1.5±0.3 (p=0.0002). However, 
in the other 16 patients, in whom the treating physician considered that there was no 
clinical improvement following therapy, no statistically significant differences in TBR were 
found when data from the first and the follow-up PET/CT scans were compared (1.6±0.3 
vs. 1.5±0.3, p=0.1416). Patients who experienced clinical improvement following therapy 
showed a non-statistically significant higher TBR at the time of disease diagnosis (1.8±0.6 
versus 1.6±0.3; p=0.12).    
Conclusions. 18F-FDG PET/CT appears to be useful in the follow-up of LVV.   
 






Large-vessel vasculitis (LVV) typically involves the aorta and its major branches 
[1]. Giant cell arteritis (GCA) and Takayasu arteritis are the most common types of LVV [2, 
3]. Nevertheless, non-infectious LVV may occur in the context of autoimmune and 
inflammatory diseases such as systemic lupus erythematosus, Sjögren’s syndrome, 
rheumatoid arthritis, spondyloarthropaties, ulcerative colitis, sarcoidosis, other systemic 
vasculitis and polymyalgia rheumatica (PMR) [4, 5, 6].  
Patients with LVV often show non-specific clinical manifestations, including back or 
chest pain, malaise, weakness, weight loss, fever and increased levels of laboratory 
inflammatory parameters (erythrocyte sedimentation rate [ESR] and C-reactive protein 
[CRP]). In some cases, structural imaging techniques may yield negative results in 
patients with early stages of the disease. In this context, a tool that may help us to make 
an early diagnosis of LVV could be of great relevance for clinicians.  
18F-FDG PET/CT was found to be of potential value to make an early diagnosis of 
large and medium vessels inflammation, even before the development of vascular 
structural changes [6-10]. It was also useful to establish the presence and extend of 
extracranial vasculitis in patients with GCA [7-11]. In this context, aortic involvement has 
been described in more than 50% of 18F-FDG PET/CT scans performed in patients with 
GCA [7, 8, 12, 13] and a positive PET/CT has been associated with a significantly higher 
risk of complications such as aneurysms, stenosis and aortic dissection [14]. In these 
patients an early and adequate therapy (including glucocorticoids with/without 
immunosuppressive drugs) and close follow-up is important to prevent these severe 
complications [2, 3]. 
Besides limitations for the early diagnosis of LVV, the structural imaging 
techniques have in some cases limitations in monitoring the vascular inflammatory 
activity. This fact highlights the need of a non-invasive sensitive tool for the follow-up of 
these patients in the clinical setting. In this context, the role of 18F-FDG PET/CT has not 
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been well established and, up to now, only a few studies involving a limited number of 
patients have been published with promising preliminary results [8, 15-18]. A recent 
guideline recommended the use of 18F-FDG PET/CT for the diagnosis of LVV. However, 
the authors of this guideline recognized that the utility of PET/CT in monitoring anti-
inflammatory therapy response is still unknown and requires further clarification [19].  
Taking all these considerations into account, the purpose of the present study was 







This study included 38 consecutive patients with LVV who were evaluated by 18F-
FDG PET/CT scan and showed abnormal 18F-FDG uptake involving mainly the aorta. One 
patient was excluded due to technical problems and poor quality of PET/CT images. 
Therefore, we assessed 37 patients (28 women and 9 men, mean± standard deviation 
[SD] age: 66.5±9.9 y.). Table 1 summarizes the main characteristics of the patients, 
including the features that led to perform PET/CT scan to determine the presence of LVV 
and the medical treatment at the time of the initial PET/CT.  
All patients included in this study had an initial 18F-FDG PET/CT scan positive for 
aortitis and a follow-up 18F-FDG PET/CT carried out 3-12 months after the initial scan 
(mean time± SD: 7.5±2.9 months).  
Twelve of the 37 patients had a previous diagnosis of typical “isolated” PMR, 3 
atypical PMR, 6 GCA, 1 retroperitoneal fibrosis, 1 panuveitis, 1 rheumatoid arthritis, and 1 
psoriatic arthritis. For the diagnosis of GCA and PMR the American College of 
Rheumatology classification criteria [20], and the criteria proposed by Chuang et al [21] 
were used. Atypical PMR was defined when patients presented aches and pain 
resembling PMR and did not fulfill the quoted criteria. 18F-FDG PET/CT scan was 
requested in patients with PMR, inflammatory arthritis and autoimmune diseases to 
determine the presence of LVV if they had persistent fever, inflammatory low back pain, 
diffuse lower limb pain, constitutional symptoms, lack of improvement with low-medium 
dose oral glucocorticoids and/or unexplained increase of ESR and CRP. In patients with 
GCA a PET/CT scan was performed to demonstrate extracranial involvement due to poor 
clinical response to glucocorticoids, unexplained low back, upper or lower limb pain, 
persistently increased ESR and CRP levels or relapses of the disease.  
In the remaining 12 patients a PET/CT scan was performed because of the 
presence of non-specific symptoms, mainly fever, asthenia, weight loss. In these cases 
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other conditions including autoimmune diseases and neoplasms had previously been 
excluded. In these 12 patients a diagnosis of “idiopathic” LVV vasculitis was made based 
on the PET/CT scan findings, the response to treatment and the clinical outcome over the 
extended follow-up. 
 Twenty-three out of the 37 patients (62.2%) were under long-term treatment 
(mean± SD: 42.6±35.5 months) at the time of the initial scan: 19 patients with 
glucocorticoid therapy (median: 10 of prednisone mg/day, interquartile range [IQR]: 4.5-
12.5) with or without methotrexate (median: 10 mg/week, IQR: 10-15) or anti-IL6 receptor 
tocilizumab therapy (median: 8 mg/kg/iv/month), and 4 patients with less than two months 
of glucocorticoid therapy (median: 20 of prednisone mg/day, IQR: 12.5-50).  
Clinical and laboratory (ESR and CRP) assessment of patients was performed at 
the time of first PET/CT scan and also at the time of the follow-up PET/CT scan.  
Clinical improvement was assessed in each patient based on the information 
included in the medical records. The treating physician considered that the patient had 
improved when clinical symptoms such as polymyalgia features, cranial ischemic 
manifestations, constitutional symptoms or other manifestation related to the underlying 
disease improved following therapy. 
The institutional review board has approved the study and all patients signed a 
written informed consent. 
 
18F-FDG PET/CT imaging 
Patients fasted for at least 6 hours before 18F-FDG injection. The serum glucose 
level was lower than 160 mg/dL in all patients (FreeStyle Optimum glucose meter, Abbott 
UK). There were no differences between the mean serum glucose level at the time of the 
first and at the time of the follow-up PET/CT scan (94.9±17.9 vs. 102.4±28.6, p=0.1937). 
Whole-body PET/CT including lower extremities was acquired 180 min after intravenous 
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injection of 7 MBq/kg of 18F-FDG. A Biograph LSO Pico 3D from Siemens Healthcare 
Molecular Imaging (Hoffman Estates, Illinois, USA) was used. First, we obtained a low 
dose CT scan without contrast enhancement for attenuation correction and anatomic 
localization, followed by a PET scan, acquiring 250 sec per bed position. Reconstructed 
images were displayed in coronal, sagittal, and axial planes. 
For image evaluation, a semiquantitative analysis of 18F-FDG uptake at the aortic 
wall was performed, calculating a target-to-background ratio (TBR) both for the initial and 
follow-up PET/CT scan. The TBR was obtained by dividing the aortic wall maximum 
standardized uptake value (SUVmax) by the blood pool SUVmax [22]. The entire aorta 
was checked and the area with the greatest intensity of uptake was considered for 
measuring the aortic wall SUVmax. CT images were carefully analyzed together with PET 
images in order to exclude the presence of atherosclerotic plaques that could show a focal 




All continuous data were expressed as mean± SD or median and IQR. The Mann-
Whitney U test was applied to determine the significance of the differences (statistical 
significance was established at p values <0.05). All the calculations were performed using 






Overall, the mean± SD TBR decreased significantly from 1.7±0.5 in the initial 
PET/CT scan to 1.5±0.3 in the PET/CT scan follow-up (p=0.0001). Twenty-one of the 
37 patients evaluated (56.8%) experienced clinical improvement after the initial 
PET/CT scan and 16 patients (43.2%) had no clinical improvement. In the 21 patients 
with clinical improvement the mean TBR decreased significantly from 1.8±0.6 to 
1.5±0.3 (p=0.0002). However, in the other 16 patients, in whom the treating physician 
considered that there was no clinical improvement following therapy, no statistically 
significant differences in TBR were found when data from the first and the follow-up 
PET/CT scans were compared (1.6±0.3 vs. 1.5±0.3, p=0.1416) (Table 2).  
In assessing inflammatory laboratory markers, the mean ESR was 40.3±35.8 
mm/1st hour (normal: 1-20 mm/1st hour) at the time of the initial PET/CT scan and 
decreased to 23.9±22.2 mm/1st hour at the time of the follow-up scan (p=0.0591). The 
mean CRP was 2.5±4.9 mg/dL at the time of the initial PET/CT scan and 1.1±1.4 
mg/dL at the time of the follow-up scan (normal: <0.5 mg/dL), p=0.3343.  
We observed a reduction of ESR and/or CRP in 23 of the 37 patients (62.2%) 
during the follow-up. In these patients the mean TBR decreased significantly from 
1.8±0.6 to 1.5±0.3 (p=0.0062). To our surprise, in the other 14 patients (37.8%) who 
did not show decrease of ESR and/or CRP at the time of the follow-up PET/CT scan, 
the TBR also decreased from 1.7±0.3 to 1.4±0.1 (p=0.0041). 
Patients who experienced clinical improvement following therapy showed higher 
TBR at the time of disease diagnosis (1.8±0.6 versus 1.6±0.3) but the difference did 
not reach statistical significance (p=0.1291).  
TBR at the time of the follow-up PET/CT scan decreased significantly from 
1.7±0.2 to 1.5±0.3 in the 23 patients who were receiving medical treatment at the time 
of the first PET/CT scan assessment (p=0.0055). A TBR reduction at the time of the 
follow-up was also observed in the 14 patients who did not receive medical treatment 
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when the first PET/CT scan was performed (1.8±0.7 to 1.4±0.3; p=0.0088) (Table 3). 
Figure 1 shows the decrease of aortic wall 18F-FDG uptake after 12 months of 
glucocorticoid and methotrexate therapy in a representative patient who experienced 
good clinical and laboratory response.  
In a further step, we analyzed the clinical implication of the information shown in 
the first 18F-FDG PET/CT scan in the management of the 37 patients. Based on these 
data, clinicians in charge of the patients modified the treatment in 21 of the 23 patients 
who were on treatment at the time of the initial PET/CT scan. In 16 of the 21 patients 
the corticosteroid dose was increased and methotrexate was also added in 12 of them. 
In the remaining 5 patients, tocilizumab therapy was added to the glucocorticoid 
treatment. Figure 2 shows a representative patient with GCA initially treated with 
glucocorticoids who had aortic inflammation confirmed by the initial PET/CT. Due to 
refractory disease characterized by relapses when prednisone dose was tapered, 
methotrexate was added. However, no clinical improvement was achieved and in a 
second PET/CT scan a TBR increased was observed. In addition, the new PET/CT 
showed supraaortic trunks involvement (arrows). Because of that, intravenous 
tocilizumab therapy was prescribed with clinical improvement associated with 
decreased TBR (18F-FDG uptake).  
Following the first PET/CT scan medical treatment with glucocorticoids alone 
(n= 5) or associated with methotrexate (n= 6) or with methotrexate alone (n= 1) was 
started by the treating clinician in 12 of the 14 patients who had not been treated prior 
to the first PET/CT scan. These results indicate that a positive PET/CT scan had 
clinical implication to make a change in the treatment in most patients. 
As shown in Table 4, the change in the therapy in 21 patients, characterized by 
increase in the dose of prednisone and/or the use of additional therapies such as 
methotrexate and/or tocilizumab, was associated with a significant reduction of TBR at 
the time of the PET/CT scan follow-up (1.5±0.3 versus 1.7±0.2 in the first study, 
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p=0.0092). In addition, a statistically significant reduction of TBR following therapy was 
observed in those patients in whom therapy was started after the first PET/CT scan 
(1.5±0.3 versus 1.9±0.8, p=0.0094).   
In assessing specifically the change of TBR for each patient, we observed that 
TBR decreased in the follow-up in 30 (81.1%) of 37 patients. Among these 30 patients, 
the mean TBR decrease was significantly higher (p=0.0431) in the 19 patients who 
experienced clinical improvement (19.6±11.9%) when compared with the 11 patients in 
whom the reduction of TBR was not associated with clinical improvement 
(11.8±12.9%). Among the 7 patients without reduction of TBR in the follow-up PET/CT 
scan, the mean increase of the TBR in the 5 patients with clinical improvement was 
lower than in the 2 who did not show clinical improvement (TBR% increase: 9.6±12.9% 






The role of 18F-FDG PET/CT scan in early diagnosis of LVV, evaluation of the 
extent of the disease [7, 8, 13] and also in the management of these patients [10, 23] has 
previously been established. In this regard, in a former report we emphasized the potential 
value of the semiquantitative analysis of 18F-FDG PET/CT images for the diagnosis of 
aortitis [11].  
In the present study, we assessed the results obtained of the semiquantitative 
analysis of aortic 18F-FDG uptake because all of our patients had aortic inflammation 
demonstrated by PET/CT. We have also visually analyzed the 18F-FDG uptake in other 
vascular territories (not shown) and these results correlated well with those obtained for 
the aorta.  
The results obtained in the present study support that 18F-FDG PET/CT may also 
be useful for monitoring the inflammatory activity in patients with LVV. In our series, the 
mean TBR decreased significantly during the follow-up in the group of patients who 
exhibited clinical improvement. However, in patients with poor clinical response no 
differences were found between the initial and the follow-up TBR results.  
Previous studies have reported a decrease or even normalization of the vessel 
wall 18F-FDG uptake after treatment in relation to clinical and laboratory improvement. In a 
retrospective study based on a visual analysis of PET/CT images including a small 
number of patients, Bleeker-Rovers et al. reported the normalization of 18F-FDG vessel 
wall uptake in 5 patients with a follow-up PET/CT after therapy, which was in keeping with 
a good clinical and laboratory treatment response [15]. Meller et al. evaluated 6 patients 
with aortitis and PET/CT scan after starting immunosuppressive therapy. They described 
the normalization of 18F-FDG uptake in 80% of the regions with initial pathological uptake 
together with clinical improvement and normalization of the laboratory parameters and 
concluded that 18F-FDG PET/CT was more reliable than MRI for monitoring inflammatory 
activity [8]. Blockmans et al. evaluated 35 patients with GCA and reported a decrease of 
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18F-FDG uptake after 3 months of glucocorticoid therapy together with the disappearance 
of symptoms and the normalization of inflammatory parameters [16]. In another 
retrospective study, PET/CT scan and clinical and laboratory improvement was observed 
in 8 of 9 patients with LVV after 3 months of glucocorticoid treatment [17]. Henes et al. 
evaluated by PET/CT the response to cyclophosphamide in patients with refractory LVV 
and demonstrated a normalization of vascular 18F-FDG uptake in 9 of the 10 patients that 
was associated with good clinical and serological response, suggesting the usefulness of 
PET/CT as an additional tool for therapeutic decisions [25]. More recently, Bruls et al. 
performed a prospective study including 18 patients with aortitis and no previous 
glucocorticoid or immunosuppressive treatment. These authors described the 
disappearance of 18F-FDG uptake after surgery and/or immunosuppressive treatment 
along with clinical improvement in all patients [18].  
Regardless of ESR and CRP results, a significant association between clinical 
improvement and TBR decrease was observed in our patients during the follow-up. This 
finding highlights the potential use of PET/CT scan to monitor the clinical outcome of 
patients with LVV. Therefore, we feel that data retrieved from PET/CT scan evaluation 
may mirror more accurately the presence of LVV involvement and the inflammatory state 
than the acute phase reactants- ESR and CRP. Moreover, we also observed changes not 
only restricted to the intensity of 18F-FDG uptake but also in the extent of the vascular 
involvement that were associated with clinical improvement. 
There are some methodological aspects that we followed at the time of performing 
18F-FDG PET/CT to assess imaging vascular inflammation in our patients with LVV. In this 
regard, in contrast to the 1-hour standard protocol applied in oncology, we feel that a 
delayed acquisition of images 2-3 hours after 18F-FDG injection is more appropriate 
allowing better visualization of vessel wall uptake [26-28]. As described in the section of 
Methods, we followed this procedure in our assessment. Experts in the field have 
indicated that for PET/CT image evaluation qualitative methods is more specific than the 
semiquantitative ones but they have lower sensitivity [29]. Based on that and also in our 
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own experience, we decided to apply in our study a semiquantitative analysis that allowed 
us the detection of subtle changes of 18F-FDG uptake during the follow-up. In this context, 
it is mandatory that the acquisition and analysis of images may be rigorously carried out, 
using the same conditions for the initial and follow-up scan. All these factors were 
considered in our study and may contribute to a more accurate assessment of vascular 
inflammatory activity. 
In our experience, a residual 18F-FDG vascular uptake is very frequently observed, 
even in patients with clinical improvement. Thus, the follow-up mean TBR for patients with 
and without clinical improvement was higher than the cutoff of 1.34 established in a 
previous study including a control population [22]. This observation is in accordance with 
previous reports in which a persistent 18F-FDG vascular uptake has been described, even 
up to 80% of cases at 6 months [30]. This uptake, even observed in asymptomatic 
patients with normal laboratory inflammatory parameters, has been attributed to persistent 
inflammatory activity, vessel wall remodeling or immune resistance and was not related to 
relapse [16, 30]. However, no studies have been conducted to analyze in depth this 
finding and the causes remain unclear. 
Remarkably, we observed that the initial mean TBR was higher in patients who 
experienced clinical improvement following therapy when compared to the patients 
without clinical improvement although the difference was not significant. Based on this 
finding, we can hypothesize that a higher initial TBR, reflecting a more intense 
inflammatory process, seems to identify a subgroup of patients who may be more 
susceptible to reach clinical improvement following therapy. We acknowledge that this 
observation needs to be confirmed in larger series of patients. 
There is still controversy on the routine monitoring and follow-up assessment of 
the patients by 18F-FDG PET/CT. With respect to this, Blockmans et al. consider that18F-
FDG PET/CT offers no additional advantage over the follow-up based on the clinical and 
laboratory monitoring of patients [31]. Nevertheless, our results indicate that18F-FDG 
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PET/CT may be useful for the management of these patients. However, it must take into 
account that repeated PET/CT scans determine radiation exposure and expenses, so 18F-
FDG PET/CT would be especially indicated in patients with poor clinical response or 
suspicion of relapse after the decrease or withdrawal of therapy. 
Our study has several limitations that should be considered. In most patients the 
follow-up PET/CT scan was requested due to a poor clinical outcome, which introduces a 
selection bias. In addition, baseline situation of the patients was very heterogeneous as 
more than sixty percent of our patients were already undergoing therapy when the first 
PET/CT scan was requested. With respect to this, the variability in the therapy and the 
different timing of follow-up PET/CT scans were also potential limitations. Nevertheless, 
we consider that our results reflect the real scenario in a clinical setting. 
 
Conclusions 
In conclusion, 18F-FDG PET/CT appears to be useful in the follow-up of patients 
with large-vessel vasculitis, especially in cases with poor clinical treatment response or 
suspicion of relapse after the decrease or withdrawal of therapy, having relevant 
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Figure 1. Initial (A) and follow-up (B) PET/CT scan showing a decrease of aortic uptake 
after treatment. 
 

















at the time 
of PET/CT 
Treatment at the time of 
initial PET/CT 
1 68/M Atypical PMR Gluteus and lower limbs pain. 
Poor treatment response. 
NP 0.1/2 Prednisone (chronic) 
2 62/F PMR Thoracic aorta aneurysm. 
Persistently increased ESR/CRP. 
NP 1.1/33 No 
3 67/F GCA Lower back and limbs pain. 
Increased ESR/CRP. 
Positive 0.4/5 MTX (chronic) 
4 60/F No* Fever, headache, good treatment response. 
Increased ESR/CRP. 
Negative 3.7/57 No 
5 50/F No* Ischemic heart disease (stents), aortobifemoral 
bypass. 
NP 0.9/7 No 
6 68/F No* Fever, headache, asthenia, weight loss, anemia. 
Increased ESR/CRP. 
Negative 25.8/94 Prednisone (8 d) 
7 81/F No* Chronic anemia, lower limbs ischemic lesions.  
Increased ESR/CRP. 
NP 0.7/62 No 
8 63/F GCA Thoracic aorta aneurysm. Positive 0.1/7 Prednisone+MTX+TCZ 
(chronic) 
9 54/F PMR Pelvic girdle pain. Poor treatment response. 
Persistently increased ESR/CRP. 
NP 1.0/77 Prednisone (chronic)  
10 74/F GCA Constitutional symptoms, malaise.  
Relapse after decreasing treatment. 
Positive 1.2/32 Prednisone (chronic) 
11 72/F PMR Poor treatment response. Chronic anemia.  
Persistent increased ESR/CRP. 
Negative 3.4/98 Prednisone (chronic) 
12 66/F Atypical PMR Scapular, low back and pelvic girdle pain.  
Poor treatment response. 
Increased ESR/CRP. 
Negative 0.4/72 No 
13 80/F GCA Fatigue, lower limbs pain. 
Increased ESR/CRP. 
Positive 2.4/26 Prednisone (chronic) 
14 68/F GCA Weight loss. 
Increased ESR/CRP. 
Positive 1.4/10 No 
15 81/M GCA Lower limbs pain. 
Increased ESR/CRP. 
Positive 1.7/15 Prednisone (chronic) 
16 68/F No* Scapular and pelvic girdle pain. 
Persistently increased ESR/CRP.  
NP 4.3/95 No 
17 62/F Atypical PMR Lower back and limbs pain. 
Increased ESR/CRP. 
NP 0.1/17 Prednisone+MTX (chronic) 
18 56/M PMR Poor treatment response.  
Abdominal aorta aneurysm.  
Increased ESR/CRP. 
Negative 0.7/22 Prednisone+MTX (chronic) 
19 82/F PMR Poor treatment response. 
Increased ESR/CRP. 
NP 0.3/8 MTX (chronic) 
20 65/F PMR Relapse after steroid withdrawal. 
Persistently increased ESR/CRP. 
NP 5.5/65 Prednisone (chronic) 
21 81/F No* Lower back and limbs pain. 
Increased ESR/CRP. 
NP 0.8/77 No 
22 72/M No* Inflammatory cervical, scapular, lower back and 
limbs pain.  
Increased ESR/CRP. 
NP 1.7/27 No 
23 79/F PMR Pelvic girdle pain.  
Increased ESR/CRP. 
Negative 1.4/66 No 
24 58/M No* Vertebrobasilar stroke. Subclavian, axillary and 
right humeral artery occlusion. Upper limbs pain. 
NP 0.1/2 No 
25 54/F Retroperitoneal 
fibrosis 
Lower limbs pain. Claudication. 
Increased ESR/CRP. 
NP 0.7/37 Prednisone (chronic) 
26 55/F No* Lower back and limbs pain. NP 0.1/9 No 
27 65/F Panuveitis Lower back pain.  
Increased ESR/CRP. 
NP 2.0/102 Prednisone (chronic) 
28 65/F PMR Morning stiffness, scapular pain.  
Poor treatment response.  
Increased ESR/CRP. 
Negative 0.1/19 Prednisone (14 d) 
29 56/M PMR Neck, shoulders, hips and lower limbs pain.  
Increased ESR/CRP. 
NP 3.5/33 Prednisone (chronic) 
30 66/F PMR Scapular and hips pain. Poor treatment response. 
Relapse after decreasing therapy. 
NP 1.1/15 Prednisone+MTX(chronic) 
31 78/F No* Constitutional symptoms, fever, chronic anemia, 
weight loss.  
Increased ESR/CRP. 
NP 10.5/120 No 
32 67/F RA Low back pain, thoracic aorta aneurysm.  
Permanently increased ESR/CRP. 
NP 0.7/11 Prednisone+MTX (14 d) 
33 55/M No* Constitutional symptoms, scapular pain. 
Good steroid response. 
NP 0.1/2 Prednisone (chronic) 
34 50/F No* Malaise, fatigue, chest pain.  
CT angiography: iliac/femoral arteries stenosis. 
NP 0.2/15 No 
35 59/F PMR Scapular, shoulders, pelvic girdle, lower limbs pain. 
Increased ESR/CRP. 
Negative 13.8/110 Prednisone (chronic) 
36 66/M Psoriatic 
arthritis 
Scapular and chest pain.  
Poor treatment response. 
NP 0.3/23 Prednisone (chronic) 
37 89/M PMR Joint pain and stiffness. 
Poor treatment response. 
Negative 0.1/19 Prednisone (59 d) 
M: male; F: female; PMR: polymyalgia rheumatica; GCA: giant cell arteritis; RA: rheumatoid arthritis; ESR: erythrocyte sedimentation rate (mm/1
st
 hour); CRP: C-
reactive protein (mg/dL); NP: not performed; MTX: methotrexate; TCZ: Tocilizumab. * Diagnosed later as having “idiopathic” large-vessel vasculitis. 
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Table 2. Overall target-to-background ratio (TBR) and according to the clinical and 
laboratory outcome. 
 
 Patients n Initial TBR Follow-up TBR P 
Overall 37 1.7±0.5 (1.2-4.1) 1.5±0.3 (1.1-2.5) 0.0001 
With clinical improvement 21 1.8±0.6 (1.4-4.1) 1.5±0.3 (1.1-2.5) 0.0002 
Without clinical improvement 16 1.6±0.3 (1.2-1.9) 1.5±0.3 (1.1-2.2) 0.1416 
With ESR and/or CRP decrease 23 1.8±0.6 (1.2-4.1) 1.5±0.3 (1.1-2.5) 0.0062 
Without ESR and/or CRP 
decrease 
14 1.7±0.3 (1.3-2.5) 1.4±0.1 (1.1-1.7) 0.0041 





Table 3. Target-to-background ratio (TBR) in patients with and without treatment at the 




 Patients n Initial TBR Follow-up TBR p 
Undergoing treatment 23 1.7±0.2 (1.4-2.0) 1.5±0.3 (1.1-2.2) 0.0055 
Without treatment 14 1.8±0.7 (1.2-4.1) 1.4±0.3 (1.1-2.5) 0.0088 
P  0.9376 0.3014  








Table 4. Target-to-background ratio (TBR) at the initial and follow-up PET/CT scan 
according to the therapeutic management of the patients. 
 
 
 Patients n Initial TBR Follow-up TBR p 
On treatment at the initial PET/CT 
Change in the therapy* 




























TBR: target-to-background ratio.  
* Based on the clinician judgment including information yielded in the PET/CT scan study. 
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